Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HD-P023 vs Teneligliptin + Empagliflozin in Healthy Volunteers
NCT06889350Phase 1Completed
- Sponsor
- Handok
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teneligliptin + empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Handok. Primary endpoints: Area under the plasma concentration versus time curve from time zero to time t at 72 hours and Peak Plasma Concentration at 72 hours. Started Mar 2025; status: completed.
02
Drugs
teneligliptin + empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06889350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889350.